cell transplantation; haemolysis ABO incompatibility between donor and recipient is encountered in 23-30% of allogeneic haematopoietic stem cell transplants (HSCT). This incompatibility is defined as major when the recipient plasma has isohaemagglutinins (IHAs) against donor red blood cell (RBC) antigens, and minor when the donor has IHAs against recipient RBC antigens. Bidirectional ABO incompatibility occurs when combined features of major and minor incompatibility coexist.
ABO incompatibility is not considered a barrier for successful HSCT. Many reports have revealed no influence on engraftment. [1] [2] [3] [4] [5] However, conflicting data still exist as to its influence on transplant outcome, graft-versus-host disease (GVHD), 6 -10 relapse [10] [11] [12] and survival. 10, [13] [14] [15] [16] Major and minor ABO incompatibilities are associated with several immunohaematological complications such as immediate or delayed haemolysis, delayed erythropoiesis and pure red cell aplasia. Many strategies have been adopted to overcome these problems. To prevent acute haemolysis of donor RBCs in the case of major ABO incompatibility, either RBC removal from donor bone marrow (BM)/peripheral blood stem cells (PBSC) or IHA removal from the recipient plasma, or both, have been used. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] To prevent acute haemolysis of recipient RBCs in the event of minor ABO incompatibility, donor BM plasma removal by centrifugation or recipient RBC dilution with group O RBCs have been used. 4 For bidirectional ABO incompatibility, both donor RBCs and plasma are removed from BM/PBSC, and plasma exchange (PE) in the recipient is performed on occasions. Each method has advantages and drawbacks. At present, there is no general agreement as to the most suitable method for each situation.
The aim of this study was to survey current practice in relation to ABO-incompatible HSCT in Italy. For this purpose, a questionnaire was designed on behalf of the Italian Bone Marrow Transplant Group (GITMO), and sent to all GITMO centres performing allogeneic HSCTs. Different procedures adopted by the various centres were compared with the experience reported in the literature.
Materials and methods
A questionnaire was sent to all 46 GITMO centres performing allogeneic HSCTs. The questionnaire was divided into three parts. For the pretransplant phase, the questions concerned immunohaematological tests performed on both the donor and recipient, for the peritransplant phase they concerned methods used to prevent immediate reactions of incompatible BM/PBSC infusion and for the post transplant phase they concerned transfusion policy in various situations and programs related to the immunohaematological monitoring of patients. The questions included in the questionnaire are listed in Appendix A. The literature review was carried out by means of a MEDLINE search, using the MeSH browser for all articles in the English language containing 'ABO blood group' and 'bone marrow transplantation' as key words and applying no date limits. A total of 140 articles were reviewed, in which a number of principle points were identified such as: influence of ABO incompatibility on GVHD, survival and engraftment; techniques to prevent the risk of haemolysis due to infusion of ABO-incompatible BM; Rh(D) incompatibility; transfusion policy and the importance of the IHA titre.
Definitions

Results
In all, 34/46 transplant centres (74%) answered the questionnaire. A total of 27 centres (79.4%) also performed HSCTs from matched unrelated donors (MUDs). The 34 centres represent 86.9% of all allogeneic HSCTs performed in Italy during 2000.
Pretransplant phase
Extensive RBC phenotyping is performed on recipients by 79.4% of the centres, on family donors by 78.7% and on MUDs by 65.3%; IAT is performed by 75.7, 71.8 and 60% of the centres on recipients, family donors and MUDs, respectively; anti-A and anti-B IHA titration is performed by 87.5, 78.1 and 68% of the centres on recipients, family donors and MUDs, respectively. In the case of MUDs these tests are carried out on a variety of materials (peripheral blood provided at different times, BM itself) and some centres perform the tests on more than one material.
Altogether, 59 .2% of centres test RBC phenotype on peripheral blood for HLA compatibility tests, 44.4% on peripheral blood provided together with bone marrow and 18.5% on bone marrow itself. A total of 11.1% of the centres believe that the ABO/Rh group performed by the donor centre is sufficient.
Peritransplant phase
Strategies adopted to prevent immediate haemolysis are reported for each situation. (15/34) . Four centres perform both sedimentation in HES and processing by a blood cell separator, and one centre removes RBCs during the T-cell depletion procedure. With regard to the residual RBC target, the responses in the questionnaire vary from 1 to 50 ml, with a range between 5 and 10 ml for the majority of the centres (40 and 33.3%, respectively).
With regard to the use of PE in the recipient, 55.8% of the centres perform it on the basis of the IHA titre (however, the titre required to start the procedure varies between 1:8 and 1:1024), whereas 41.1% of the centres never perform PE in the recipient and 2.9% always perform PE.
Minor ABO incompatibility. A total of 81.2% of the centres always removes the plasma from the donor BM, while the remaining 18.7% removes the plasma only if the donor IHA titre is above a threshold level, which, however, ranges from 1:16 to 1:256.
Major and minor Rh(D) incompatibility. In the case of major Rh(D) incompatibility, about half of the centres (54.8%) takes no action, while the other half performs various procedures and, in particular, removal of RBCs from BM (32.2%), PE on the recipient if the agglutinin titre is high (6.4%), anti-D-immunoglobulin infusion (3.2%) and plasma removal from BM (3.2%). With minor Rh(D) incompatibility, 75% of centres do not take any action and 25% remove the plasma from BM.
Post transplant phase
Transfusion policy. For transfusion policy in cases of major and minor ABO incompatibility (RBC, platelets and plasma transfusion) see Tables 1 and 2 . Transfusion policy is maintained until recipient RBCs are no longer detectable by 73.5% of the centres, while 14.7% maintain it only for the first month, 2.9% for 2 months, 5.8% for 3 months and 2.9% for 6 months post transplant. A total of 24/28 centres (85.7%) takes into account the Rh(D) donor/recipient difference for transfusion requests.
Monitoring. The majority of centres (58%) plans blood group monitoring every month, 19.3% every 3-6 months, while the remaining 22.7% of the centres plans monitoring in a range between 2-3 weeks and 1-3 months. Half of the centres takes into account only ABO and Rh(D) systems, while the other half monitors the extensive erythrocyte phenotype. A total of 42.8% of the centres monitors anti-A and anti-B IHA titre monthly, 19% every 2 weeks, 14.2% every week. 19% of the centres plan monitoring between 1 and 6 months, while 4.7% do it only on demand.
Discussion
The first feature to emerge from this survey concerns the high heterogeneity of the procedures adopted by GITMO centres in relation to ABO-incompatible allogeneic HSCT.
Transfusion policy
An heterogeneous pattern of immunohaematologic and transfusion policy has also been revealed by a recent survey conducted by the French Society of Bone Marrow Transplantation (SFGM) in 25 French centres. 30 Despite clear indications offered by the literature for the best transfusion management of ABO incompatibility in HSCT 4, 31 (Table 3) , our survey showed that among Italian centres procedures are strongly based on local preferences for both major and minor incompatibility (Tables 1 and 2 ).
Many centres always transfuse O group RBCs in order to overcome ABO differences between donor and recipient. In any event, it must be remembered that some cases of haemolysis of O group-transfused RBCs have been described as being due to a 'bystander' effect 32 in the setting of minor ABO incompatibility.
Heterogeneity of behaviour is particularly evident with the plasma and platelet concentrates (PC), also partly due to different ways of preparing PCs, that is, from whole blood donation (pooled PC) or from single donor aphaeresis, which lead to a final product more or less contaminated by RBCs. 33 In the case of PC transfusion, both the antigenic group of platelets and the antibodies present in the plasma should be considered. Platelets have A and B antigens on their membrane, either intrinsic or passively adsorbed from the plasma. 34 For this reason, a transfusion of incompatible platelets can stimulate production of anti-A and anti-B antibodies and also induce refractoriness to PCs. Platelet survival after ABO-incompatible platelet transfusion is generally only slightly influenced by ABO antibodies. 35 However, approximately 7% of blood donors have platelets that carry significantly more A and B blood group antigens on their surface and ABO mismatched transfusion from these 'high expresser' donors could be responsible for cases of poor platelet survival. 36 A minor yield can also be due to platelet destruction from circulating immunocomplexes (anti-A/anti-B antibodies and ABH soluble substances). 37 Incompatibility of the plasma contained in CP could also be relevant. Although there are usually no clinical problems but only small laboratory signs of haemolysis, 38 serious complications with the transfusion of small quantities of plasma have been described. 39 For this reason, we believe it is advisable not to transfuse incompatible plasma and to always use ABO compatible or plasma-poor PCs.
The survival of transfused platelets is not influenced by Rh donor/recipient diversity as Rh antigens are not present on platelets. 34, 35 The risk of alloimmunization after Rh-incompatible platelet transfusion using PCs prepared by modern methods appears to be low in immunocompromised patients. However, it is recommended 34, 40 Our study also dealt with other aspects of the ABO-incompatible transplantation such as pretransplant immunohaematological tests and methods of treating ABO incompatibility during the transplant procedure and monitoring, demonstrating that a considerable degree of heterogeneity also exists in these areas. We noted, moreover, that there are no specific indications in the literature with respect to any of these aspects.
Pretransplant tests
Extensive erythrocyte phenotyping, indirect antiglobulin testing and anti-A and anti-B IHA titration are not carried out on all recipient/donor pairs, and furthermore these tests seem to be carried out in a smaller percentage of MUD cases as compared to family donors. In the case of transplants from a MUD, 11% of the centres does not repeat blood group typing and considers the results provided by the donor centre as sufficient. Knowing the extensive recipient and donor erythrocyte phenotype is useful both in the assessment of erythroid chimerism 41 and in those cases of early 42, 43 or late haemolysis by antibodies directed against erythrocyte antigens not of the ABO system. 44, 45 IAT is useful to detect possible 'dangerous universal blood donors' and to check reactivity to erythrocyte antigens not of the ABO system. It was recently reported that Kell is not only the earliest marker that appears in erythropoiesis but it is also expressed on myeloid progenitor cells, 46 and alloantibodies against antigens of the Kell blood group system should be considered as a potential cause of neutropenia as well as a potential cause of delayed erythropoiesis.
Peritransplant strategies
Strategies adopted to prevent peritransplant complications vary according to the kind of incompatibility.
In the case of major ABO incompatibility the choice is among RBCs removal, PE in the recipient or both of them. 3, 17, 18, [21] [22] [23] [24] [25] [26] 28, 35, 48, 49 but in the most recent practice the use of a blood cell separator is gaining ground. There are two main problems relating to the methods of RBC removal.
The first is infusion of incompatible RBCs in quantities that may vary but are potentially sufficient to induce an acute haemolytic reaction in vivo. Infusion of a quantity of RBCs of up to 38 ml caused no problems. 21 Sedimentation in HES, separation on a Ficoll gradient and processing by blood cell separators allow a reduction in residual RBCs to well below this limit. It should be noted that for 6.6% of the centres that answered the questionnaire, the residual RBC target was 50 ml.
The second problem is possible loss of mononuclear cells. Up to a median of 52.9 and 52.4% loss for mononuclear cells and CFU-GM has been reported, 21, 22, [24] [25] [26] 28 which can also result in delayed engraftment. On the whole, at least seven cases of graft failure using a blood cell separator with sedimentation on Ficoll have been described. 21, 24, 26 Use of the blood cell separator without Ficoll leads to a mononuclear cell loss of 10-40%. 29, 50 This issue seems to be significant especially for patients with severe aplastic anaemia (SAA) and for those transplanted from an MUD. It has therefore been suggested 40 that RBC removal should be carried out in the case of transplantation from a sibling, while the use of PE in the recipient is to be preferred in cases of SAA and in transplants from an MUD. However, it is now generally possible to recover more than 90% of the mononuclear cells using a blood cell separator. 50 A total of 17.6% of the centres performs the removal of RBCs only on the basis of the titre of anti-A and anti-B IHA titre in the recipient, but adopting variable threshold levels. The problem of acute haemolysis has not been However, on the basis of available data, it seems impossible to determine a safety threshold level for avoidance of haemolysis.
The use of PE in the recipient, which allows for the removal of over 80% of intravascular IgG and IgM, 51 divides the Italian centres into two almost equal groups. In the literature, the use of PE alone has been described in about 150 patients with an IHA titre varying from 1:2 to 1:256, generally without haemolytic problems. 27, 52 However, two cases of acute haemolysis have also been described. 2 In some cases, PE was unsuccessful in reducing the antibody titre.
1, 3 Bensinger et al 26 have reported 58 cases of patients treated with PE alone; they found no difference in the time needed to achieve engraftment compared with patients receiving RBC-depleted BM.
Other methods used as an alternative to or in association with PE such as plasma immunoadsorption and whole blood immunoadsorption showed a delay in the time needed to reach RBC transfusion independence and a greater incidence (14/91) of failure to reach diminution of IHA titres. 26, 51 The transfusion of donor-type RBCs 1, 53 has been used with the aim of adsorbing the IHAs, but cases of renal failure have been described. 3, 52 Donor-type fresh frozen plasma has also been used for in vivo adsorption of recipient IHAs. 54 The risks related to PE, namely citrate toxicity, thrombocytopenia and transmission of infections are all almost abolished by currently available technology and by the use of virus-inactivated plasma 55 or virus-free plasma substitutes. Moreover, there is the possibility of a rebound 1, 2, 19, 20 of antibody production with consequent post transplant haemolysis. Bensinger et al 2 have reported that 29 out of 81 patients had a return of anti-RBC antibodies to a titre of 1:16 or more during the post transplant period. The probability of rebound was low when the pre-PE antibody titre was 1:8 or less, and very high when the titre was 1:128 or higher.
Rowley 56 suggests that unmodified BM can be safely infused into patients with IHA titres of up to 1:16. Bussel et al 48 suggest that removal of RBCs should always be undertaken, and that PE should be performed only if the IHA titre in the recipient is X1:512.
On the basis of currently available data, it is not possible to provide clear guidelines concerning the removal of RBCs and/or the PE. In particular, no data are available concerning which threshold titre of anti-A and anti-B IHAs in the recipient would determine a preference for one or the other, or a decision to adopt either method.
In the case of minor incompatibility immediate haemolysis is not a clinically significant issue. Lasky et al 4 have reported that two out of seven patients transplanted with uncentrifuged BM developed laboratory evidence of mild haemolysis. These two patients received a BM volume of 27-30 ml/kg body weight with an IgM IHA titre of 1:64. No patient who received plasma-depleted BM (remaining plasma o5 ml/kg body weight) developed acute haemolysis. Some authors suggest that plasma should be removed only if the IHA titre of the donor is above a predefined threshold (eg X1:128), while others, and we ourselves, also suggest that this should always be done. 40, 56 The most frequent problem relating to minor ABO incompatibility is delayed haemolysis due to the production of IHAs by the donor lymphocytes. [57] [58] [59] [60] [61] [62] Delayed haemolysis is independent of the pretransplant IHAs titre 57 and can also be associated with serious consequences and even fatality. 61, [63] [64] [65] [66] Risk factors for this complication are T-cell depletion and GVHD prophylaxis with cyclosporin A without methotrexate. 32, [57] [58] [59] It is suggested that the immunosuppressive effects of T-cell depletion and cyclosporin A (T-cell specific) in the absence of methotrexate (B-cell suppressor) could result in enhanced B-cell proliferation leading to T-cell independent antibody production. An increased risk of delayed haemolysis has been reported after PBSC transplantation. 61, [65] [66] [67] [68] [69] However, no evidence of haemolysis was found by Rowley et al 70 in a recent study comparing BM and PBSC as the source of haematopoietic stem cells in patients receiving cyclosporin A plus methotrexate as GVHD prophylaxis.
Regarding Rh(D) incompatibility, delayed haemolysis may be a problem, 71, 72 and if the recipient has anti-D antibodies induced, for example, by previous pregnancies or by recent transfusions of PCs contaminated with Rh(D)-positive RBCs, 73 removal of RBCs from the donor BM is recommended. Delayed haemolysis due to anti-E alloantibodies has also been reported. 74 In comparison with major, minor Rh(D) incompatibility is more frequently linked to haemolytic complications, although these are rarely of clinical significance. 4, 57, [75] [76] [77] Some authors have suggested the use of prophylactic Rh(D) immune globulin. 78 
Monitoring
Another interesting aspect that emerges from the questionnaire is that only 65% of the centres carry out post transplant monitoring of the IHA titre, and only 14% perform strict monitoring in the first post transplant weeks, while according to the literature 61, 67, 79 cases of early, possibly serious haemolysis can occur within minor ABO incompatibility. IHAs, even at low titre, can be responsible for delayed erythropoiesis in transplanted patients with major ABO incompatibility and also for a number of cases of pure red cell aplasia. [80] [81] [82] [83] [84] [85] Furthermore, the cases of alloimmune haemolysis due to incompatibilities involving non-ABO RBC antigens emphasize the importance of close immunohaematological monitoring of patients undergoing HSCT even in the absence of ABO/Rh mismatch. 42 We believe that in cases of major ABO incompatibility, it is advisable to monitor recipient IHA titres on a weekly basis, especially when pretransplant levels are high. This is particularly important to allow detection of an increase in titre when this coincides with the appearance of donorderived RBCs. In the case of minor ABO incompatibility, we believe that it is advisable to perform a direct antiglobulin test and antibody screening tests twice weekly for 3 weeks, once weekly for the following 2 weeks and finally once a month until results are negative.
ABO incompatibility in allogenic HSCT is still an unresolved issue. Even if it does not represent a contraindication to transplantation, it can cause serious clinical problems such as immediate or delayed haemolysis, delayed engraftment and pure red cell aplasia. Very recent reports have also indicated an influence on survival, particularly in cases of bidirectional incompatibility. 15 There are no unanimous guidelines in the literature for management of ABO incompatibility related problems, which may lead to potentially dangerous practices. Scientific societies should thus consider implementation of guidelines in view of the fact that on-site accreditation inspections frequently reveal deficiencies. 86 
